Results 171 to 180 of about 231,777 (344)
Organoids and organ‐on‐a‐chips are advancing reproductive system research. In the female reproductive system, applications include cancer organoid models, placental chips, and hormone simulation models. For the male reproductive system, research focuses on drug resistance mechanisms, co‐culture platforms, and infertility studies. These refined in vitro
Hongqi Zhang +6 more
wiley +1 more source
Hormone stimulation of androgen receptor mediates dynamic changes in DNA methylation patterns at regulatory elements [PDF]
Vineet K. Dhiman +3 more
openalex +1 more source
Impact of organic pollutants on phenotype and gene expression in human breast cancer cells
ABSTRACT Human exposure to industrial chemical compounds is widespread and, although often beneficial, prolonged contact may contribute to disease development, including cancer. While many studies have shown organic pollutants (OP) are cytotoxic, few have explored how long‐term exposure alters cell phenotype.
Camila Confortin +7 more
wiley +1 more source
ABSTRACT Humans are chronically exposed to mixtures of environmental contaminants. Exposure to endocrine‐disrupting chemicals (EDCs) contributes to increased health impairment observed globally. This study aimed to evaluate the endocrine‐disruptive and oxidative stress potential of a human‐relevant, complex chemical mixture in vitro.
Josefin Engelhardt +5 more
wiley +1 more source
Differential Regulation of Androgen and Glucocorticoid Receptors by Retinoblastoma Protein [PDF]
Jianming Lü, Mark Danielsen
openalex +1 more source
RNA‐based fusion panels using targeted next‐generation sequencing of formalin‐fixed paraffin‐embedded (FFPE) tumour tissue specimens have been used for a few years from patients with various tumour types to detect rearrangements/fusions. Using the bioinformatic approaches the data obtained from RNA sequencing (RNAseq) can also be used for small ...
Pranav Dorwal +14 more
wiley +1 more source
Oestrogen and androgen receptors in melanoma [PDF]
P Rümke, J.-P. Persijn, C. B. Korsten
openalex +1 more source
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol +5 more
wiley +1 more source

